Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

K. Reich; A. Blauvelt; A. Armstrong; R. G. Langley; T. Fox; J. Huang; C. Papavassilis; E. Liang; P. Lloyd; G. Bruin

doi:10.1111/bjd.14965

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

K. Reich, A. Blauvelt, A. Armstrong, R. G. Langley, T. Fox, J. Huang, C. Papavassilis, E. Liang, P. Lloyd, G. Bruin

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

52 Citations (Scopus)

Original language	English
Pages (from-to)	752-758
Number of pages	7
Journal	British Journal of Dermatology
Volume	176
Issue number	3
DOIs	https://doi.org/10.1111/bjd.14965
Publication status	Published - Mar 1 2017

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.14965

Cite this

Reich, K., Blauvelt, A., Armstrong, A., Langley, R. G., Fox, T., Huang, J., Papavassilis, C., Liang, E., Lloyd, P., & Bruin, G. (2017). Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 176(3), 752-758. https://doi.org/10.1111/bjd.14965

Reich, K, Blauvelt, A, Armstrong, A, Langley, RG, Fox, T, Huang, J, Papavassilis, C, Liang, E, Lloyd, P & Bruin, G 2017, 'Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis', British Journal of Dermatology, vol. 176, no. 3, pp. 752-758. https://doi.org/10.1111/bjd.14965

@article{58e4348bf58f4aeb9b03c07f9de32cfd,

title = "Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis",

author = "K. Reich and A. Blauvelt and A. Armstrong and Langley, {R. G.} and T. Fox and J. Huang and C. Papavassilis and E. Liang and P. Lloyd and G. Bruin",

note = "Funding Information: The authors would like to thank the patients and investigators who participated in the studies. BioScience Communications, New York, NY, provided editorial assistance, supported by Novartis Pharma AG. Publisher Copyright: {\textcopyright} 2016 British Association of Dermatologists",

year = "2017",

month = mar,

day = "1",

doi = "10.1111/bjd.14965",

language = "English",

volume = "176",

pages = "752--758",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

AU - Reich, K.

AU - Blauvelt, A.

AU - Armstrong, A.

AU - Langley, R. G.

AU - Fox, T.

AU - Huang, J.

AU - Papavassilis, C.

AU - Liang, E.

AU - Lloyd, P.

AU - Bruin, G.

N1 - Funding Information: The authors would like to thank the patients and investigators who participated in the studies. BioScience Communications, New York, NY, provided editorial assistance, supported by Novartis Pharma AG. Publisher Copyright: © 2016 British Association of Dermatologists

PY - 2017/3/1

Y1 - 2017/3/1

UR - http://www.scopus.com/inward/record.url?scp=85005992410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005992410&partnerID=8YFLogxK

U2 - 10.1111/bjd.14965

DO - 10.1111/bjd.14965

M3 - Article

C2 - 27518376

AN - SCOPUS:85005992410

SN - 0007-0963

VL - 176

SP - 752

EP - 758

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 3

ER -

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this